John Alexander Cairns

Academic article

Show author(s) (2022). “Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England. PharmacoEconomics - Open.
Show author(s) (2022). Protocol for data extraction: How real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy. BMJ Open.
Show author(s) (2022). Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy. BMC Cancer. 15 pages.

Show author(s) (2021). Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway. Quality of Life Research. 1-12.
Show author(s) (2021). How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. BMC Cancer. 21 pages.

Show author(s) (2020). HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective? PharmacoEconomics - Open. 529-539.
Show author(s) (2020). Disagreement on cancer drug decisions in Europe. International Journal of Technology Assessment in Health Care. 232-238.

Show author(s) (2019). What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. Health Policy. 130-139.

Show author(s) (2018). The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. European Journal of Cancer. 89-98.
Show author(s) (2018). Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLOS ONE. 1-23.

Show author(s) (2017). Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. European Journal of Health Economics. 1-13.
Show author(s) (2017). Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. Value in Health. 799-808.

Show author(s) (2015). Why do some countries approve a cancer drug and others don’t? Journal of Cancer Policy. 21-25.

Show author(s) (2010). Think twice before you book? Modelling the choice of public vs private dentist in a choice experiment. Health Economics. 670-682.

Show author(s) (2007). Time preferences for health in northern Tanzania - An empirical analysis of alternative discounting models. PharmacoEconomics (Auckland). 73-88.

Show author(s) (2006). Preferences over dental restorative materials among young patients and dental professionals. European Journal of Oral Sciences. 15-21.

Show author(s) (2004). Repeated follow-up as a method for reducing non-trading behaviour in discrete choice experiments. Social Science and Medicine. 2211-2218.

Report

Show author(s) (2004). Elicting Patient and Professional Preferences for Dental Restorations. .

Academic lecture

Show author(s) (2004). Eliciting patient and professional preferences for dental restorations.
Show author(s) (2004). Eliciting patient and professional preferences for dental restorations.

Academic anthology/Conference proceedings

Show author(s) (2017). Cancer Biomarkers: Ethics, Economics and Society. Megaloceros Press.

Abstract

Show author(s) (2004). Preferences by dental professionals and teenage patients related to attributes of restorative materials. European Journal of Paediatric Dentistry.

Academic literature review

Show author(s) (2017). A systematic literature review of health state utility values in head and neck cancer. Health and Quality of Life Outcomes. 1-13.

Fields of competence